What is the difference between Ubrelvy and Nurtec?

Orange County Migraine & Headache Center

Ubrelvy and Nurtec are 2 new oral medications approved for the acute treatment of migraine in adults. Both are in the same category of migraine medication called the “gepants.”  Ubrelvy is an oral tablet 50 mg & 100 mg and is taken as needed for migraine and may be repeated in 2 hours to a maximum of 200 mg in a 24-hour period. Nurtec is a 75 mg orally dissolving tablet and is taken one tablet in a 24-hour period for migraine. Both are well-tolerated and show no evidence of medication overuse headache or vasoconstriction.

Good candidates for Ubrelvy or Nurtec include those for whom the triptans are not well-tolerated, not adequately effective, or are contraindicated. Please schedule an appointment to discuss whether Ubrelvy or Nurtec may be appropriate for you. Both have good access and affordability for those with commercial insurance.

 

To make an appointment, please call 949-861-8717.

May I take Fioricet after taking Ubrelvy for acute migraine?

Orange County Migraine & Headache CenterFioricet and other Butalbital containing medications are CYP3A4 inducers and will cause Ubrelvy to be potentially less effective.  CYP3A4 is an enzyme and activation of this enzyme with an inducer like Fioricet will decrease exposure to Ubrelvy. So it would not be recommended to take both in the same 24-hour period.

 

To make an appointment, please call 949-861-8717.

May I take my Imitrex (Sumatriptan) in addition to Ubrelvy in the same 24-hour period?

Orange County Migraine & Headache CenterYes. In the clinical trials with Ubrelvy individuals were allowed to take a 2nd dose of Ubrelvy or take their triptan like Sumatriptan in 2 hours after dosing if not headache free. There does not appear to be any safely issue taking both Ubrelvy and a triptan in the same 24-hour period.

 

To make an appointment, please call 949-861-8717.

Orange County Migraine & Headache Center’s Response to COVID-19

In light of COVID-19, public health authorities are stating it is necessary for everyone to maintain social distance for your safety and the safety of all of our communities. We therefore strongly urge you to either turn your next visit into a phone visit or postpone your next office visit unless it is absolutely unavoidable. If you feel it is necessary to come in to the office, for example you are due for a Botox procedure or need a nerve block, then only come in if you are healthy, not running a fever, not coughing, and not short of breath. We may take your temperature and will ask additional screening questions before allowing you to enter our exam rooms.

If you are not feeling well, particularly with a cough, shortness of breath, or a fever, you should not come to the clinic and instead contact your primary care provider for further directions. The COVID-19 situation is evolving rapidly and daily and we expect to update this guidance as the situation changes.

At this time we are still staffing the office, answering our phones, and handling prescription issues as well as prior authorizations. Employees are asked to stay home if not feeling well. In addition, extra precautions are being taken by our landlord in cleaning handrails, elevator buttons, and other areas used often.

In summary, please keep your follow-up appointment but allow us to turn your visit into a phone visit instead of an in-person visit. You will get the same amount of time we would give with an in-person visit, prescription refills will be handled, and any needed prior authorizations will be handled. Thank you for your patience in this evolving situation.

We pray for good health for all of you,

Dr. Susan Hutchinson & Dr. Molly Rossknecht

March 19, 2020

Should I take the 50 or the 100 mg dose of Ubrelvy, the new migraine medication?

Orange County Migraine & Headache Center

Both the 50 & the 100 mg doses of Ubrelvy (Ubrogepant) showed good efficacy over placebo in clinical trials. Both doses are FDA approved for the acute treatment of migraine with or without aura in adults. Either dose may be used. If you start with 50 mg and are not headache free in 2 hours, then you may consider increasing to the 100 mg as your usual dose. Importantly, we have options for dosing. Once taken, either dose may be repeated in 2 hours and the maximum in 24 hours is 200 mg. To learn more, go to www.Ubrelvy.com

To make an appointment, please call 949-861-8717.

Ubrelvy & Reyvow Now Available

Good news…. we now have 2 new medications for the acute treatment of migraine.  Both are oral tablets and represent alternatives for those who have unmet acute migraine treatment needs. The triptans, first introduced in the United States in 1992, have been the mainstay of treatment for years. They include Imitrex, Maxalt, Zomig, Relpax, Axert, Amerge, and Frova. Most are generic and inexpensive. Are the new medications better? For some patients, they may be.

The goals for acute migraine treatment are to be headache free and back to full function in 2 hours after taking the acute medication like Imitrex. If your migraine treatment is not consistently bringing you to headache freedom in 2 hours you would be a candidate for Ubrelvy or Reyvow. In addition, if you are putting up with “triptan sensations” like neck/chest tightness, flushing, fatigue, nausea, or worsening of the headache before it gets better, you may tolerate Ubrelvy or Reyvow better. Lastly, if you have a contraindication to the triptans due to coronary artery disease, peripheral vascular disease, or multiple cardiac risk factors, these new medications would be safer as neither Reyvow nor Ubrelvy cause vasoconstriction.

Ubrelvy (Ubrogepant) is the first oral “gepant” to be FDA approved. It is an oral CGRP (calcitonin gene-related peptide) antagonist and works by blocking at the CGRP receptor site. In binding to this receptor site, it prevents the CGRP peptide that is released during migraine to attach and thereby, prevents the pathway of migraine. Numerous studies have shown that CGRP gets elevated during migraine. To learn more go to www.scienceofmigraine.com. Ubrelvy does not cause vasoconstriction, is very well tolerated in clinical trials, and so far, does not appear to cause medication overuse headache. It is available as a 50 mg & a 100 mg tablet and may be repeated in 2 hours. Ubrelvy comes in a package of 10 and for patients with commercial insurance, is available for $10 per 10 tablets per month. To learn more, go to www.Ubrelvy.com and to access the savings program, go to www.Ubrelvy.com/savings. If you are up-to-date on your visit with us, we may be willing to send in a Rx for Ubrelvy prior to your next visit. If interested, please email us at info@ocmigraine.org.

Reyvow (Lasmiditan) works differently than Ubrelvy. It is a 5-HT1F serotonin receptor agonist and is referred to as a “ditan” Reyvow binds to the 5-HT1F receptor activating it, which then inhibits pain pathways and inhibits release of neuropeptides like CGRP. It is not associated with vasoconstriction or medication overuse headache. However, it crosses into the central nervous system (CNS) and as such, can cause drowsiness and sedation. As a result, it is a controlled medication and is Schedule 5 by the DEA. Schedule 5 represents medications that have the least addictive potential. Reyvow comes as a 50 and 100 mg strength tablet and is dosed as 50 mg, 100 mg or 200 mg as a single dose in a 24-hour period. There is a driving restriction for 8 hours due to the potential sedation and dizziness seen in clinical trials.  Reyvow may be useful as a rescue option when an individual is home for the day with a moderate to severe migraine and does not plan on driving for 8 hours. As headache specialists, we are hopeful that Reyvow can take the place of Butalbital products including Fiorinal & Fioricet as well as Hydrocodone Products such as Vicodin & Norco. To learn more go to www.Reyvow.com. Reyvow has a savings program for those with commercial insurance. Using the savings program, an individual should be able to get 8 tablets per month for zero copay. Information about the savings program is available at www.Reyvow.com.  Because Reyvow is a controlled medication, please make an appointment with us if you are interested in trying. We need to carefully review the potential side effects with you.

Other medications will be coming soon including Rimegepant, another oral gepant for acute migraine. In 1-2 years, Atogepant, a 3rd oral gepant, should be available and will be for the prevention of migraine.

This is truly an exciting time in migraine. With new treatment options, comes new hope for a brighter future for all individuals with migraine.

We look forward to working with each of you to optimize your headache treatment plan.

 

Dr. Susan Hutchinson & Dr. Molly Rossknecht

February 12, 2020

What are some good websites for learning about new treatments for migraine that are not overly promotional?

Orange County Migraine & Headache CenterOur office recommends the following websites as good resources to learn more about new treatments for migraine:

Our practice website www.ocmigraine.org is also a good source for learning about new migraine treatments and we try to update regularly.

 

To make an appointment, please call 949-861-8717.

I heard that a new migraine medication called Reyvow has been approved. What is it?

Reyvow is a new migraine medication FDA approved for acute migraine treatment. Another name for it is Lasmiditan. Although FDA approved, it cannot be prescribed until the DEA decides what category to put it in as it can cause dizziness and sedation. There will be some sort of warning on not driving for a certain number of hours after taking. Despite the sedation & dizziness as possible side-effects, it does not cause any vasoconstriction like the triptans and may be useful for patients who cannot take the triptans due to cardiac issues and for those for whom the triptans are ineffective or poorly tolerated. We expect Reyvow to be available by February 2020.

 

To make an appointment, please call 949-861-8717.

What is Ubrogepant? I heard it would be available soon.

Ubrogepant is an oral tablet for the acute treatment of migraine.  It targets the calcitonin gene related peptide (CGRP) receptor and prevents CGRP from binding. This blocks the migraine process. Unlike the current monthly anti-CGRP injections, this is for acute migraine treatment. It may be a great option for those dissatisfied with their current acute treatment. Ubrogepant will be an oral tablet 50 or 100 mg and can be repeated in 2 hours for a migraine attack. Unlike Reyvow, another new migraine medication, Ubrogepant does not cause drowsiness or dizziness. We think it will be available by January 2020.

 

To make an appointment, please call 949-861-8717.